Enzyme product approved for rare hand disorder

Traynor, Kate
March 2010
American Journal of Health-System Pharmacy;3/15/2010, Vol. 67 Issue 6, p416
Academic Journal
The article reports on the approval of collagenase clostridium histolyticum or Xiaflex for injection from Auxilium Pharmaceuticals Inc. to treat Dupuytren's contracture in adults by the U.S. Food & Drug Adminstration (FDA). FDA says that Xiaflex is the first product with its labeling approved by the agency for the treatment of the rare disease affecting the hands and prevents the normal use of fingers. It states that Xiaflex consists of two purified microbial collagenases.


Related Articles

  • Financings Roundup.  // BioWorld Today;10/2/2009, Vol. 20 Issue 190, p6 

    This article reports that Auxilium Pharmaceuticals Inc. of Malvern, Pennsylvania culminated its public stock offering and has generated net proceeds amounting to 115.7 million U.S. dollars. Auxilium sold 3.45 million shares for 34.50 U.S. dollars each. The company continues to wait for a U.S....

  • Auxilium Files Xiaflex BLA, Seeks Nod in Dupuytren's Contracture. Boggs, Jennifer // BioWorld Today;3/4/2009, Vol. 20 Issue 41, p1 

    This article reports on a biologics license application submitted by Auxilium Pharmaceuticals Inc. to the U.S. Food & Drug Administration for the approval of its Xiaflex in Dupuytren's contracture. Xiaflex is a formulation of collagenase enzyme. Dupuytren's contracture is a rare condition...

  • Auxilium's Xiaflex Setback May Be 'Last Box Checked'.  // Bioworld Week;6/23/2009, Vol. 17 Issue 25, p5 

    The article reports the advisory review to be held for Xiaflex, a formulation of collagenase enzyme developed by Auxilium Pharmaceutical Inc. for treatment of Dupuytren's contracture. Auxilium has blamed administration at the U.S. Food and Drugs Administration (FDA) for this blow. William...

  • Auxilium stock up on FDA approval of Peyronie's therapy. Shaffer, Catherine // BioWorld Today;12/9/2013, Vol. 24 Issue 235, p1 

    The article reports on the drug approval given by the U.S. Food and Drug Administration (FDA) to Xiafex (collagenase clostridium histolyticum), the first approved drug manufactured by Biospecifics Technology Corp. and partner Auxilium Pharmaceuticals Inc. for Peyronie's disease, as of December...

  • Auxilium 'Finally' Wins Xiaflex Approval for Rare Hand Disease. Young, Donna // BioWorld Today;2/4/2010, Vol. 21 Issue 23, p1 

    This article reports on the increase in shares of Auxilium Pharmaceuticals Inc. on February 3, 2010 following the approval given by the U.S. Food and Drug Administration (FDA) to the firm's Xiaflex drug indicated to treat Dupuytren's contracture. Dupuytren's contracture is a progressive...

  • Despite Concerns, Panel Favors Auxilium's Xiaflex in Dupuytren's. Young, Donna // BioWorld Today;9/17/2009, Vol. 20 Issue 179, p1 

    The article reports on the decision by the Arthritis Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to approve the drug collagenase clostridium histolyticum branded as Xiaflex from Auxilium Inc. Xiaflex is designed to treat Dupuytren's disease, a progressive disease that...

  • Auxilium's Xiaflex Setback May Be 'Last Box Checked.'. Osborne, Randy // BioWorld Today;6/19/2009, Vol. 20 Issue 117, p1 

    The article reports that Xiaflex, a formulation of collagenase enzyme for Dupuytren's contracture from Auxilium Pharmaceuticals Inc., will be subjected to an advisory review by the Food and Drug Administration (FDA) in the U.S. According to the Malvern, Pennsylvania-based company, the review...

  • Auxilium Files BLA for Dupuytren's Contracture.  // Bioworld Week;3/9/2009, Vol. 17 Issue 10, p3 

    The article reports on the submission of Auxilium Pharmaceuticals Inc.'s license application for its Xiaflex, a formulation of collagenase enzyme in the U.S. It notes that the drug will be the first pharmacological therapy for Dupuytren's contracture, when the Food and Drug Administration will...

  • Auxilium Raising $107M on Heels of Xiaflex Panel Win. Morrison, Trista // BioWorld Today;9/28/2009, Vol. 20 Issue 186, p1 

    The article reports on a 3 million share public offering issued by Auxilium Pharmaceuticals Inc. one week after a U.S. Food and Drug Administration (FDA) panel unanimously approved its Xiaflex for the treatment of Dupuytren's disease. The approval bid for Xiaflex is supported by 13 clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics